Switch theme
Sign up to access all valuation multiples
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
2020
680
LTM Revenue $144M
LTM EBITDA -$92.3M
$65.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Immatics has a last 12-month revenue (LTM) of $144M and a last 12-month EBITDA of -$92.3M.
In the most recent fiscal year, Immatics achieved revenue of $156M and an EBITDA of $34.5M.
Immatics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immatics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $144M | XXX | $156M | XXX | XXX | XXX |
| Gross Profit | $144M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$92.3M | XXX | $34.5M | XXX | XXX | XXX |
| EBITDA Margin | -64% | XXX | 22% | XXX | XXX | XXX |
| EBIT | -$110M | XXX | -$38.6M | XXX | XXX | XXX |
| EBIT Margin | -76% | XXX | -25% | XXX | XXX | XXX |
| Net Profit | -$67.4M | XXX | $15.2M | XXX | XXX | XXX |
| Net Margin | -47% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Immatics's stock price is $5.
Immatics has current market cap of $655M, and EV of $65.0M.
See Immatics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $65.0M | $655M | XXX | XXX | XXX | XXX | $-0.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Immatics has market cap of $655M and EV of $65.0M.
Immatics's trades at 0.4x EV/Revenue multiple, and 1.9x EV/EBITDA.
Equity research analysts estimate Immatics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immatics has a P/E ratio of -10.9x.
See valuation multiples for Immatics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $655M | XXX | $655M | XXX | XXX | XXX |
| EV (current) | $65.0M | XXX | $65.0M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | 0.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.9x | XXX | 43.1x | XXX | XXX | XXX |
| EV/FCF | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmatics's last 12 month revenue growth is -43%
Immatics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Immatics's rule of 40 is -208% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immatics's rule of X is -172% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Immatics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -43% | XXX | -31% | XXX | XXX | XXX |
| EBITDA Margin | -64% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 119% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -208% | XXX | -21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -172% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 95% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 125% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immatics acquired XXX companies to date.
Last acquisition by Immatics was XXXXXXXX, XXXXX XXXXX XXXXXX . Immatics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Immatics founded? | Immatics was founded in 2020. |
| Where is Immatics headquartered? | Immatics is headquartered in United States of America. |
| How many employees does Immatics have? | As of today, Immatics has 680 employees. |
| Who is the CEO of Immatics? | Immatics's CEO is Dr. Harpreet Singh, PhD. |
| Is Immatics publicy listed? | Yes, Immatics is a public company listed on NAS. |
| What is the stock symbol of Immatics? | Immatics trades under IMTX ticker. |
| When did Immatics go public? | Immatics went public in 2020. |
| Who are competitors of Immatics? | Similar companies to Immatics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Immatics? | Immatics's current market cap is $655M |
| What is the current revenue of Immatics? | Immatics's last 12 months revenue is $144M. |
| What is the current revenue growth of Immatics? | Immatics revenue growth (NTM/LTM) is -43%. |
| What is the current EV/Revenue multiple of Immatics? | Current revenue multiple of Immatics is 0.5x. |
| Is Immatics profitable? | Yes, Immatics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Immatics? | Immatics's last 12 months EBITDA is -$92.3M. |
| What is Immatics's EBITDA margin? | Immatics's last 12 months EBITDA margin is -64%. |
| What is the current EV/EBITDA multiple of Immatics? | Current EBITDA multiple of Immatics is -0.8x. |
| What is the current FCF of Immatics? | Immatics's last 12 months FCF is -$190M. |
| What is Immatics's FCF margin? | Immatics's last 12 months FCF margin is -131%. |
| What is the current EV/FCF multiple of Immatics? | Current FCF multiple of Immatics is -0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
